Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report)'s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $11.67, but opened at $12.21. Zentalis Pharmaceuticals shares last traded at $12.12, with a volume of 23,635 shares.
Analysts Set New Price Targets
ZNTL has been the subject of several research analyst reports. Wedbush boosted their price target on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a "neutral" rating in a report on Wednesday, February 28th. HC Wainwright lowered their price target on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 8th. Finally, Stifel Nicolaus decreased their price objective on shares of Zentalis Pharmaceuticals from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, May 8th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $37.14.
Get Our Latest Stock Report on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Stock Up 2.6 %
The firm has a 50 day simple moving average of $13.43 and a two-hundred day simple moving average of $13.28. The stock has a market capitalization of $850.58 million, a P/E ratio of -3.60 and a beta of 1.82.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.91. The business had revenue of $40.56 million for the quarter, compared to the consensus estimate of $35.00 million. During the same quarter in the prior year, the company earned ($1.07) earnings per share. On average, research analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.85 earnings per share for the current year.
Insider Buying and Selling
In related news, insider Diana Hausman sold 3,356 shares of Zentalis Pharmaceuticals stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $12.62, for a total transaction of $42,352.72. Following the completion of the transaction, the insider now owns 373,876 shares of the company's stock, valued at $4,718,315.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.10% of the stock is currently owned by insiders.
Institutional Trading of Zentalis Pharmaceuticals
Hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD grew its holdings in Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company's stock worth $54,999,000 after purchasing an additional 585,644 shares during the period. ProShare Advisors LLC increased its position in Zentalis Pharmaceuticals by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 15,436 shares of the company's stock valued at $243,000 after buying an additional 1,274 shares in the last quarter. 49 Wealth Management LLC acquired a new position in Zentalis Pharmaceuticals during the 1st quarter worth approximately $172,000. Carson Advisory Inc. bought a new position in Zentalis Pharmaceuticals in the first quarter worth approximately $201,000. Finally, Commonwealth Equity Services LLC grew its stake in Zentalis Pharmaceuticals by 12.2% in the first quarter. Commonwealth Equity Services LLC now owns 60,895 shares of the company's stock valued at $960,000 after acquiring an additional 6,640 shares during the period.
About Zentalis Pharmaceuticals
(
Get Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
See Also
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
